NUVB Q4 2025 Earnings — Nuvation Bio Inc. Revenue & Financial Results | Market Cap Arena

NUVBNuvation Bio Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+633.1% YoY

Gross Profit

$41M99.0% margin

Operating Income

-$34M-81.3% margin

Net Income

-$37M-87.4% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

+219.1%

Cash Flow

Operating Cash Flow

$144M

Free Cash Flow

$144M

Stock-Based Comp.

-$28M

Balance Sheet

Total Assets

$595M

Total Liabilities

$289M

Stockholders' Equity

$306M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$6M	+633.1%
Gross Profit	$41M	$1M	+2672.0%
Operating Income	-$34M	-$54M	+36.9%
Net Income	-$37M	-$49M	+26.0%

Revenue Segments

License

$35M60%

Product

$23M40%

Geographic Segments

JAPAN

$28M52%

UNITED STATES

$23M43%

CHINA

$3M6%